The Drug-Induced Respiratory Disease Website and App

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.i Flash (fulminate) pulmonary edema

XI. Miscellaneous

XI.b Chest pain (acute or subacute) lone or prominent

XI. Miscellaneous

XI.d Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.f Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.g Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.j Myocardial stunning

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.t Torsades de pointe

XII. Cardiovascular involvement / toxicity

XII.w Asystole

XII. Cardiovascular involvement / toxicity

XII.af Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.aq Wandering pacemaker

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.n Pulmonary alveolar proteinosis (PAP) (secondary)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.f Hypoxemia - Low oxygen saturation (may occur in isolation)

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.x Transient hacking cough

VI. Pulmonary vasculopathy

VI.e Fat/oil embolism - The FES embolism syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.u Multiple organ dysfunction/failure (MODS/MOF)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.f Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.g Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.o Coronary artery disease (subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.v Hypertrophic cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.ai Cardiotoxicity

XV. Pathology

XV.n Path: Pulmonary alveolar proteinosis pattern (PAP pattern)

XV. Pathology

XV.p Path: Exogenous lipoid pneumonia

XV. Pathology

XV.bu Path: Pulmonary peliosis

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.f Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.ai Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.ak Late left ventricular dysfunction/failure

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.h Overload pulmonary edema (including posttransfusional (TACO))

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.i Respiratory arrest - Apnea

XI. Miscellaneous

XI.d Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.f Cardiomyopathy (acute, subacute, chronic)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.h Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.n Pulmonary alveolar proteinosis (PAP) (secondary)

I. Interstitial/parenchymal lung disease

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (a.k.a. Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.x Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.aa Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ad Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.ao Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.au The chemotherapy lung

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.c ARDS and the hemolytic-uremic syndrome (HUS)

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.k Bronchiectasis

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.f Pneumothorax

V. Pleural and/or pericardial involvement

V.ab Pneumothorax, bilateral

VI. Pulmonary vasculopathy

VI.b Pulmonary arterial hypertension

VI. Pulmonary vasculopathy

VI.c Pulmonary veno-occlusive disease

VI. Pulmonary vasculopathy

VI.f Hemolytic and uremic syndrome (HUS). See also under Xaf

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VII. Mediastinal involvement

VII.h Pneumomediastinum

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.t Vocal cord paresis/paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.f Hiccup

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.o Pneumorachis

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.n Tumor lysis syndrome (TLS)

XI. Miscellaneous

XI.b Chest pain (acute or subacute) lone or prominent

XI. Miscellaneous

XI.k Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.s Cavitation/necrosis of lung tumor or metastases

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.b Valvular heart disease and/or dysfunction

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.f Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.g Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.s Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ai Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.bl Atrial fibrillation

XIII. Neoplastic conditions

XIII.a Lung cancer

XIII. Neoplastic conditions

XIII.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

XIII. Neoplastic conditions

XIII.d Malignant mesothelioma (pleural, pericardial)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also pattern If)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.i Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XV. Pathology

XV.l Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XV. Pathology

XV.ak Path: Pulmonary veno-occlusive disease (PVOD)

XV. Pathology

XV.am Path: Thrombosis in pulmonary arterioles/venules

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.af Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bf Imaging: Tumoral cavitation

XVI. Imaging

XVI.bl Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVI. Imaging

XVI.bw Imaging: Air or an air crescent around lung tumor or metastase(s)

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.j Mucormycosis (pulmonary, tracheobronchial or systemic)

XVII. Infections & related conditions

XVII.r Fungal infection (pulmonary/extrapulmonary)

XVII. Infections & related conditions

XVII.af Reactivation of a prior pulmonary infection (TB, melioidosis)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.g BAL: Atypical epithelial cells (at times poetically named

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.t Pneumoconiosis (silicosis, talcosis...)

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.n Alveolar hemorrhage (subclinical, or as a BAL feature)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.o Airway hyperresponsiveness

V. Pleural and/or pericardial involvement

V.f Pneumothorax

V. Pleural and/or pericardial involvement

V.ab Pneumothorax, bilateral

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.b Pulmonary arterial hypertension

VI. Pulmonary vasculopathy

VI.l Acute pulmonary vasoconstriction and PHT

VII. Mediastinal involvement

VII.h Pneumomediastinum

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.c Upper airway obstruction other than angioedema or hematoma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.i Midline destructive lesions

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.m Drug foreign body in the airway

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.w Uvulitis, uvular edema

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ah Tracheal polyps

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ai Nasal, palatal and/or pharyngeal pathology

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ak Rhinitis medicamentosa

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ap Airway foreign body

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.aw Foreign body in the airway

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.k Trismus (lockjaw)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.o Pneumorachis

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.h Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.o Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.u Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.x ANCA positivity. Subclinical or with clinical manifestations

X. Systemic/Distant conditions, syndromes and reactions

X.ac Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.ad Skin purpura, ecchymoses or necrosis

X. Systemic/Distant conditions, syndromes and reactions

X.as Scleroderma renal crisis

XI. Miscellaneous

XI.b Chest pain (acute or subacute) lone or prominent

XI. Miscellaneous

XI.j Pulmonary emphysema - Lung cysts or bullae

XI. Miscellaneous

XI.k Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.n Death following exposure or poisoning

XI. Miscellaneous

XI.aa Barotrauma (incl. pneumothorax, pneumomediastinum, interstitial ephysema...)

XI. Miscellaneous

XI.at Sneezing (may cause pulmonary barotrauma)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.f Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.g Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.y Pneumopericardium

XII. Cardiovascular involvement / toxicity

XII.ae Acute aortic dissection

XII. Cardiovascular involvement / toxicity

XII.af Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.aj Systemic arterial thrombosis

XII. Cardiovascular involvement / toxicity

XII.ap Coronary artery dissection

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.c Carboxyhemoglobinemia

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.s Path: Pneumoconiosis (silicosis, talcosis, talcoma)

XV. Pathology

XV.w Path: Pulmonary edema (see also II/IIa)

XV. Pathology

XV.aw Path: Skin vasculopathy/vasculitis/fibrin thrombi

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

IV. Airway involvement

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.e Fat/oil embolism - The FES embolism syndrome

VI. Pulmonary vasculopathy

VI.ad Right ventricular outflow tract compression

VII. Mediastinal involvement

VII.c Mediastinal lipomatosis

VII. Mediastinal involvement

VII.g Hemomediastinum - Mediastinal hematoma

VII. Mediastinal involvement

VII.h Pneumomediastinum

VII. Mediastinal involvement

VII.j Compression of mediastinal structures/organs

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.g Tracheal narrowing - Sabre sheath trachea

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.f Hiccup

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.m Epidural thoracic lipomatosis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.p Disordered breathing during sleep - Sleep apnea

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.v Generalized myopathy/muscle weakness

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.n Tumor lysis syndrome (TLS)

X. Systemic/Distant conditions, syndromes and reactions

X.as Scleroderma renal crisis

X. Systemic/Distant conditions, syndromes and reactions

X.ba Rhabdomyolysis (see also under Xj)

XI. Miscellaneous

XI.r Rib fracture

XI. Miscellaneous

XI.ac Vertebral compression fracture

XI. Miscellaneous

XI.ae Cushing syndrome

XI. Miscellaneous

XI.ap Diminished efficacy of antineoplastic immunotherapy

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.v Hypertrophic cardiomyopathy

XVI. Imaging

XVI.at Imaging: Subpleural fat deposits

XVI. Imaging

XVI.au Imaging: Mediastinal fatty deposits

XVII. Infections & related conditions

XVII.a Respiratory tract infection incl. pneumonia

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.d Pneumocystis jiroveci pulmonary colonization

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.j Mucormycosis (pulmonary, tracheobronchial or systemic)

XVII. Infections & related conditions

XVII.m Fungal airway infection

XVII. Infections & related conditions

XVII.o Nocardia pulmonary/systemic infection

XVII. Infections & related conditions

XVII.r Fungal infection (pulmonary/extrapulmonary)

XVII. Infections & related conditions

XVII.v Strongyloides stercoralis hyperinfection (w/wo DAH)

XVII. Infections & related conditions

XVII.w Hypogammaglobulinemia - Antibody deficiency

XVII. Infections & related conditions

XVII.ai A falsely negative/indeterminate IGRA test result